Work

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Year: 2019

Type: article

Abstract: Ann Oncol 2019; (doi:10.1093/annonc/mdy522) In the original article, the wrong supplementary material was accidentally uploaded. This has now been corrected. The Publisher apologizes for the error. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancerAnnals of OncologyVol. 30Issue 2PreviewPatients with HPV+ oropharyngeal squamous cell carcinoma were assigned to dose and volume de-escalated radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy in an effort to limit treatment-related toxicity while preserving efficacy. Full-Text PDF Open Archive

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz171

Authors: T.Y. Seiwert, C.C. Foster, E.A. Blair, T.G. Karrison, N. Agrawal, J.M. Melotek, L. Portugal, R.J. Brisson, A. Dekker, S. Kochanny, Z. Gooi, M.W. Lingen, V.M. Villaflor, D.T. Ginat, D.J. Haraf, E.E. Vokes

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,250

OpenAlex ID: W2997195902

FWCI: 4.434

Cites:

Cited by: 40

Related to: 10